Detalles de la búsqueda
1.
Mitophagy in Intestinal Epithelial Cells Triggers Adaptive Immunity during Tumorigenesis.
Cell
; 174(1): 88-101.e16, 2018 06 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-29909986
2.
Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors.
Mol Ther
; 2024 May 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38751112
3.
3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids.
EMBO J
; 38(12)2019 06 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-31036555
4.
Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers.
Cancer Immunol Immunother
; 72(9): 2905-2918, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-36688995
5.
Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
Int J Cancer
; 145(7): 1935-1945, 2019 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30860598
6.
Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies.
Cancer Immunol Immunother
; 67(1): 25-38, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28879551
7.
Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies-the German Cancer Consortium approach.
Cancer Immunol Immunother
; 67(4): 513-523, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29380009
8.
Tailoring cells for clinical needs: Meeting report from the Advanced Therapy in Healthcare symposium (October 28-29 2017, Doha, Qatar).
J Transl Med
; 16(1): 276, 2018 10 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30305089
9.
Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
Cytotherapy
; 19(2): 235-249, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27887866
10.
Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors.
J Immunol
; 195(5): 2493-501, 2015 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26232436
11.
CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.
J Cell Mol Med
; 20(7): 1287-94, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27008316
12.
Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Int J Cancer
; 139(8): 1799-809, 2016 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27253354
13.
NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.
Cancer Immunol Immunother
; 65(4): 485-92, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26559813
14.
Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.
Mol Ther
; 23(2): 330-8, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25373520
15.
Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.
Cancer Immunol Immunother
; 64(5): 621-34, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25711293
16.
Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.
Cytotherapy
; 17(8): 1139-51, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26072027
17.
A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth.
Int J Cancer
; 134(11): 2547-59, 2014 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24243620
18.
T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing.
Blood
; 120(22): 4334-42, 2012 Nov 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-22898597
19.
Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion.
Cytotherapy
; 16(6): 835-44, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24582456
20.
Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D-CAR-Engineered NK Cells.
Cells
; 13(3)2024 Jan 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38334638